Bolt Biotherapeutics: Mixed Financial Results
Update: 2025-11-12
Description
Bolt Biotherapeutics reported a third-quarter loss of $7.1 million, or $3.72 per share, surpassing Wall Streets expectations of $5.07 per share. The company also generated $2.2 million in revenue. However, their stock value has significantly dropped from $12.84 a year ago to $4.69, indicating a challenging market performance.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
